Skip to Main Content

Close

ASH
ASH Clinical News
ASH Image Bank Open External Link
ASH News Daily
ASH-SAP
Blood Journals
Hematology
The Hematologist
International

header search

search input Search input auto suggest

filter your search

Search

Menu

Issues
- Current issue
- All Issues
CMEOpen External Link
About

Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 2024, Issue 1

December 6 2024

Hematology Cover Image for Volume 2024, Issue 1

In this Issue

Ham-Wasserman Lecture
A Little Less Conversation, a Little More Action: An Outcome Equity Roadmap for Children and AYAs With Leukemia and Lymphoma
A Shifting Landscape: Treatment of MCL
Addressing Unmet Needs In T-Cell Lymphomas
Adult ALL Advancements: Optimizing Cure in 2024
Adult CAR-T Outcomes: Beyond the Acronyms (OS, PFS, CRS, ICANS)
ALPS, CVID, and LGL: When Autoimmune Cytopenias are a Marker of Underlying Immune Disease
AML M&Ms: How to Integrate Mutations and MRD Data
Anticoagulation SOS: Navigating Monitoring Conundrums
Beyond TTP: “Atypical” TMAs for the Hematologist
Challenges and Opportunities of Sickle Cell Care in Africa
Challenges In Cancer-Associated Thrombosis
Chasing Zebras: Navigating Rare Myeloid Neoplasms
Follicular Lymphoma: Playing the Long Game
Handling Bad News: How to Best Manage TP53 Myeloid Disease
Hematologic Challenges at the End of Life
Hematologic Management of the Patient with Heavy Menstrual Bleeding
HIT-and-Run: Challenges in Diagnosis and Management of Heparin-Induced Thrombocytopenia
Integrating New Therapies into the Management of Classical Heme Disorders
Ironing Out the Wrinkles: Managing Iron Overload in Different Clinical Scenarios
It’s a Different World: CLL 2024
Monoclonal Gammopathies: When the Clone Is More than a Positive Laboratory Finding
Moving the Needle in Hodgkin Lymphoma
MPN Practice Pearls: Profiling, Pegylated IFN and Pregnancy
Newly Diagnosed Multiple Myeloma: Many Choices and More Questions
Not All Lymphadenopathy is Lymphoma: Lymphoproliferative Diseases of Immune Dysregulation
Optimizing Non-Curative Therapies for Sickle Cell Disease
Overcoming Post-Transplant Relapse: How To Win the Battle Royale
Sex Hormones, Contraceptives, and Thrombotic Risk: Where Are We Now?
The Expanding Landscape of Treatment for ITP
Vascular Anomalies, Vascular Malformations, and the Role of the Hematologist
Errata

Table of Contents

Ham-Wasserman Lecture

Sickle cell disease in India: the journey and hope for the future

Kalpna Gupta,Lakshmanan Krishnamurti,Dipty Jain

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

A Little Less Conversation, a Little More Action: An Outcome Equity Roadmap for Children and AYAs With Leukemia and Lymphoma

The lasting impact of the ACA: how Medicaid expansion reduces outcome disparities in AYAs with leukemia and lymphoma

Xin Hu,Sharon M. Castellino,Xu Ji

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment

Puja J. Umaretiya,Rahela Aziz-Bose,Colleen Kelly,Kira Bona

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Sharing is caring: a network collaborative approach to identify and address barriers in accessing clinical trials in adolescents and young adults with leukemia and lymphoma

Caroline Hesko,Jessica Heath,Michael E. Roth,Nupur Mittal

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

A Shifting Landscape: Treatment of MCL

Your chemo is no good here: management of high-risk MCL

Yazeed Sawalha,Kami Maddocks

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL

E. Silkenstedt,M. Dreyling

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma

Zachary D. Epstein-Peterson,M. Lia Palomba

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Addressing Unmet Needs In T-Cell Lymphomas

BV and beyond: how to incorporate novel agents into PTCL management

Imran A. Nizamuddin,Neha Mehta-Shah

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Through thick and thin: confronting the aggressive cutaneous T-cell lymphomas

Robert Stuver,Steven M. Horwitz

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

The role of stem cell transplant (auto and allo) in PTCL and CTCL

Peter Dreger,Norbert Schmitz

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Adult ALL Advancements: Optimizing Cure in 2024

Ph+ ALL: new approaches for upfront therapy

Marlise R. Luskin

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Ph− ALL: immunotherapy in upfront treatment

Matthias Stelljes

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Transplant in ALL: who, when, and how?

Curtis Marcoux,Partow Kebriaei

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Adult CAR-T Outcomes: Beyond the Acronyms (OS, PFS, CRS, ICANS)

Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies

Xin Shelley Wang,Samer A. Srour

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Late complications and long-term care of adult CAR T-cell patients

Michael R. Bishop

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Mitigating and managing infection risk in adults treated with CAR T-cell therapy

Nadeem Tabbara,M. Veronica Dioverti-Prono,Tania Jain

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

ALPS, CVID, and LGL: When Autoimmune Cytopenias are a Marker of Underlying Immune Disease

Professional illustration by Patrick Lane, ScEYEnce Studios

Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase δ syndrome

V. Koneti Rao,Stefania Pittaluga,Gulbu Uzel

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Common variable immunodeficiency: autoimmune cytopenias and advances in molecular diagnosis

Charlotte Cunningham-Rundles,Jean-Laurent Casanova,Bertrand Boisson

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Large granular lymphocyte leukemia: a clonal disorder with autoimmune manifestations

Tony Marchand,Cédric Pastoret,Aline Moignet,Mikael Roussel,Thierry Lamy

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

AML M&Ms: How to Integrate Mutations and MRD Data

Mutations and MRD: clinical implications of clonal ontogeny

Jerald Radich

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient

Michael Heuser,Rabia Shahswar

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Mutation- and MRD-informed treatments for transplant-ineligible patients

Curtis A. Lachowiez,Courtney D. DiNardo

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Anticoagulation SOS: Navigating Monitoring Conundrums

DOACs: role of anti-Xa and drug level monitoring

Siraj Mithoowani,Deborah Siegal

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Troubleshooting heparin resistance

Cheryl L. Maier,Jean M. Connors,Jerrold H. Levy

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Warfarin and heparin monitoring in antiphospholipid syndrome

Prabal Mittal,Zara Sayar,Hannah Cohen

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Beyond TTP: “Atypical” TMAs for the Hematologist

Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy

Anuja Java

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Transplant-associated TMA: the conundrum of diagnosis and treatment

Ang Li,Sarah E. Sartain

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease

Brittany M. Salter,Mark Andrew Crowther

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

New definitions for antiphospholipid syndrome: ready for clinical use?
Evidence-Based Minireview

Andrew B. Song,Rebecca K. Leaf

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Challenges and Opportunities of Sickle Cell Care in Africa

Newborn screening initiatives for sickle cell disease in Africa

Obiageli E. Nnodu,Chinwe Onyinye Okeke,Hezekiah Alkali Isa

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Transfusions, disease-modifying treatments, and curative therapies for sickle cell anemia in Africa: where are we now?

Isaac Odame,Godwin Nosakhare Bazuaye

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

The intersection of sickle cell disease, stigma, and pain in Africa

Kofi A. Anie

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Challenges In Cancer-Associated Thrombosis

Management of anticoagulation in patients with brain metastasis

Eva. N. Hamulyák,Shlomit Yust-Katz,Avi Leader

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Trousseau syndrome: management of refractory VTE

Jeffrey I. Zwicker

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Treatment of VTE in the thrombocytopenic cancer patient

Florian Moik,Cihan Ay

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Chasing Zebras: Navigating Rare Myeloid Neoplasms

The spectrum of Ph-negative disease: CNL and CSF3R-related disorders

Robert P. Hasserjian

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

BPDCN: state of the art

Naveen Pemmaraju

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

How to think about acute leukemia of ambiguous lineage

Olga K. Weinberg

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Follicular Lymphoma: Playing the Long Game

In pursuit of a functional cure for follicular lymphoma

Judith Trotman,Janlyn Falconer

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

The POD24 challenge: where do we go from here for early progressors?

Patrizia Mondello,Carla Casulo

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Sequencing bispecific antibodies and CAR T cells for FL

David A. Russler-Germain,Nancy L. Bartlett

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Predicting bispecific antibody failure in diffuse large B-cell lymphoma
Evidence-Based Minireview

Allison Barraclough,Eliza A. Hawkes

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Handling Bad News: How to Best Manage TP53 Myeloid Disease

Are TP53 mutations all alike?

Terrence N. Wong,Daniel C. Link

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Nontransplant treatment approaches for myeloid neoplasm with mutated TP53

Ansh K. Mehta,Marina Konopleva

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Transplant options and outcomes for TP53 myeloid disease

Hugo F. Fernández,Asmita Mishra

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Hematologic Challenges at the End of Life

Challenges in hospice and end-of-life care in the transfusion-dependent patient

Rachel Rodenbach,Thomas Caprio,Kah Poh Loh

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Anticoagulation at the end of life: whether, when, and how to treat

Anna L. Parks

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

End-of-life care for people with sickle cell disease: barriers to and facilitators of high-quality care

Rushil V. Patel,Emily E. Johnston

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Updates on strategies to integrate palliative care in hematologic malignancy
Evidence-Based Minireview

Wil L. Santivasi,Thomas W. Leblanc

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Hematologic Management of the Patient with Heavy Menstrual Bleeding

Quantifying menorrhagia and overview of nonsurgical management of heavy menstrual bleeding

Allison P. Wheeler,Celeste O. Hemingway

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

von Willebrand disease and heavy menstrual bleeding: when and how to test

Juliana Perez Botero

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Heavy menstrual bleeding clinics for adolescents

Maureen Baldwin,Kristina M. Haley,Janice M. Staber

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

HIT-and-Run: Challenges in Diagnosis and Management of Heparin-Induced Thrombocytopenia

Practical guide to the diagnosis and management of heparin-induced thrombocytopenia

Jori May,Adam Cuker

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Approaches to management of HIT in complex scenarios, including cardiac surgery

Oluwatayo Adeoye,Guoliang Zheng,Oluwatoyosi A. Onwuemene

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Demystifying autoimmune HIT: what it is, when to test, and how to treat

Marie Scully,William A. Lester

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Integrating New Therapies into the Management of Classical Heme Disorders

Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease

Volker H. Haase,Tetsuhiro Tanaka,Mark J. Koury

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Luspatercept: a treatment for ineffective erythropoiesis in thalassemia

Khaled M. Musallam,Ali T. Taher

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Givosiran: a targeted treatment for acute intermittent porphyria

Amy K. Dickey,Rebecca K. Leaf

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Ironing Out the Wrinkles: Managing Iron Overload in Different Clinical Scenarios

Diagnosis and management of hereditary hemochromatosis: lifestyle modification, phlebotomy, and blood donation

Domenico Girelli,Giacomo Marchi,Fabiana Busti

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept

Norbert Gattermann

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Porphyria cutanea tarda: a unique iron-related disorder

Rebecca K. Leaf,Amy K. Dickey

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

It’s a Different World: CLL 2024

Risk-stratification in frontline CLL therapy: standard of care

Eugen Tausch,Christof Schneider,Stephan Stilgenbauer

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

The evolving frontline management of CLL: are triplets better than doublets? How will we find out?

Kerry A. Rogers,Jennifer A. Woyach

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Relapsed/refractory CLL: the role of allo-SCT, CAR-T, and T-cell engagers

Arnon P. Kater,Tanya Siddiqi

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Monoclonal Gammopathies: When the Clone Is More than a Positive Laboratory Finding

MGCS: where do we stand today?

David Iberri,Michaela Liedtke

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Renal manifestations of MGUS

Frank Bridoux,Samih H. Nasr,Bertrand Arnulf,Nelson Leung,Christophe Sirac,Arnaud Jaccard

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Neurological manifestations of MGUS

M. Teresa Cibeira,Luis Gerardo Rodríguez-Lobato,Aida Alejaldre,Carlos Fernández de Larrea

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Moving the Needle in Hodgkin Lymphoma

Has PD-1 blockade changed the standard of care for cHL?

Thomas M. Kuczmarski,Ryan C. Lynch

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

When should we use it? The role of brentuximab vedotin in 2024

Joseph G. Schroers-Martin,Ranjana Advani

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

When to use stem cell transplantation for classical Hodgkin lymphoma

Miguel-Angel Perales,Sairah Ahmed

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

MPN Practice Pearls: Profiling, Pegylated IFN and Pregnancy

Molecular profiling in MPN: who should have it and why?

Ashlyn Chee,Adam J. Mead

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Pegylated interferon: the who, why, and how

Jean-Jacques Kiladjian

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Pregnancy: MPN management before, during, and after pregnancy

Joan How,Gabriela Hobbs

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?
Evidence-Based Minireview

Helen Ajufo,Jennifer Vaughn

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Newly Diagnosed Multiple Myeloma: Many Choices and More Questions

What is the ideal approach—doublet, triplet, or quadruplet(s)?

Shaji K. Kumar

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Transplant in myeloma: who, when, and why?

Aurore Perrot

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supportive care in myeloma—when treating the clone alone is not enough

Sonja Zweegman,Niels W. C. J. van de Donk

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Not All Lymphadenopathy is Lymphoma: Lymphoproliferative Diseases of Immune Dysregulation

Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy

Sally Nijim,David C. Fajgenbaum

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

IgG4-related disease for the hematologist

Luke Y. C. Chen

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

EBV and post-transplant lymphoproliferative disorder: a complex relationship

Nader Kim El-Mallawany,Rayne H. Rouce

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Optimizing Non-Curative Therapies for Sickle Cell Disease

Practical guide for disease-modifying medication management of children and adolescents with sickle cell disease

Joseph Walden,Susan Creary

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Beyond IV push: alternative methods for management of acute pain in SCD

Melissa Azul,Amanda M. Brandow

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Novel clinical care models for patients with sickle cell disease

Pablo Bartolucci

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Should we use bisphosphonates to treat bone complications in sickle cell disease?
Evidence-Based Minireview

Jahnavi Gollamudi,Oyebimpe Adesina

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Overcoming Post-Transplant Relapse: How To Win the Battle Royale

Biology of post-transplant relapse: actionable features

Giorgio Orofino,Luca Vago

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Novel conditioning and prophylaxis regimens for relapse prevention

Antonella Mancusi,Loredana Ruggeri,Antonio Pierini

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Maintenance strategies for relapse prevention and treatment

Emily Geramita,Jing-Zhou Hou,Warren D. Shlomchik,Sawa Ito

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Sex Hormones, Contraceptives, and Thrombotic Risk: Where Are We Now?

Estrogen, progestin, and beyond: thrombotic risk and contraceptive choices

Leslie Skeith,Shannon M. Bates

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Gender-affirming hormone therapy in the transgender patient: influence on thrombotic risk

Hannah King,Thalia Padilla Kelley,Joseph J. Shatzel

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing

Luuk J. J. Scheres,Saskia Middeldorp

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?
Evidence-Based Minireview

Leslie Padrnos,Radhika Gangaraju

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

The Expanding Landscape of Treatment for ITP

Insights on treatment of adult ITP: algorithm for management and role of multimodal therapy

Waleed Ghanima,Adam Cuker,Marc Michel

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

ITP in pregnancy: diagnostics and therapeutics in 2024

Annemarie E. Fogerty

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

On the horizon: upcoming new agents for the management of ITP

Michele P. Lambert

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Vascular Anomalies, Vascular Malformations, and the Role of the Hematologist

Molecular landscape and classification of vascular anomalies

Emmanuel Seront,Angela Queisser,Laurence M. Boon,Miikka Vikkula

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Targeted medical therapies for vascular anomalies

Alexandra Borst

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Hemostasis and thrombosis risks and management in vascular anomalies

Shelley E. Crary

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Potential and emerging therapeutics for HHT
Evidence-Based Minireview

Harish Eswaran,Raj S. Kasthuri

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Errata

Platton S, Sivapalaratnam S, Raheja P. Diagnosis and laboratory monitoring of acquired hemophilia A. Hematology Am Soc Hematol Educ Program. 2023;2023(1):11-18.

S Platton,S Sivapalaratnam,P Raheja

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Molina JC, Rotz S. Acute lymphoblastic leukemia in young adults: which up-front treatment? Hematology Am Soc Hematol Educ Program. 2023;2023(1):573-580.

JC Molina,S Rotz

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Anandappa A, Curran E. Challenges to successful outcomes in AYAs with ALL and potential solutions. Hematology Am Soc Hematol Educ Program. 2023;2023(1):587-592.

A Anandappa,E Curran

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Cover Image

Cover Image
Front Matter
Table of Contents
Back Matter

Latest
Most Read
Most Cited

Targeted medical therapies for vascular anomalies

T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma

Transplant in ALL: who, when, and how?

Ph− ALL: immunotherapy in upfront treatment

Ph+ ALL: new approaches for upfront therapy

American Society of Hematology
2021 L Street NW, Suite 900
Washington, DC 20036
TEL +1 202-776-0544
FAX +1 202-776-0545

ASH Publications

Blood
Blood Advances
Blood Global Hematology
Blood Immunology & Cellular Therapy
Blood Neoplasia
Blood Red Cells & Iron
Blood Vessels, Thrombosis & Hemostasis
Hematology, ASH Education Program
ASH Clinical News
ASH-SAP
The Hematologist

American Society of Hematology

ASH Home
ASH Image Bank
ASH Store

Advocacy
Education
Meetings
Research

Copyright 2025 by American Society of Hematology

Cookie Settings
Privacy Policy
Cookie Policy
Terms of Use
Contact Us

This Feature Is Available To Subscribers Only

Sign In or Create an Account